检索结果 - John Reader

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Complex synthetic chemical libraries indexed with molecular tags.

    Complex synthetic chemical libraries indexed with molecular tags. 由 Michael Ohlmeyer, R. N. Swanson, Lawrence W. Dillard, John Reader, G Asouline, Ryouji KOBAYASHI, Michael Wigler, W. Clark Still

    出版 1993
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis

    Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis 由 Melissa Works, F Yin, Catherine Yin, Ying Ying Yiu, Kenneth Shew, Thanh-Thuy Tran, Nahoko Dunlap, Jennifer S. Lam, Timothy J. Mitchell, John Reader, Paula Stein, Annalisa D’Andrea

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

    The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 由 Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Kathy Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, D. H. Williams, John Reader, Ian Collins, Michelle D. Garrett

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

    CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs 由 Mike I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth Smith, Kathy Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John Reader, Louis Chesler, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma 由 Mike I. Walton, Paul D. Eve, Angela Hayes, Alan T. Henley, Melanie Valenti, Alexis K. de Haven Brandon, Gary Box, Kathy Boxall, Matthew Tall, Karen E. Swales, Thomas P. Matthews, Tatiana McHardy, Michael Lainchbury, James Osborne, Jill V. Hunter, Neil D. Perkins, G. Wynne Aherne, John Reader, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

    Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing 由 John Reader, Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung, Jane Scanlon, Nicolas Proisy, Glynn Addison, John Ellard, Nelly Piton, Suzanne Taylor, Michael Cherry, Martin Fisher, Kathy Boxall, Samantha Burns, Michael I. Walton, Isaac M. Westwood, Angela Hayes, Paul D. Eve, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Rob L. M. van Montfort, D. H. Williams, G. Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett, Ian Collins

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: